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into the US marketplace. METHODS: Generic ﬂuoxetine
became available in August 2001. Pharmacy claims 
data from January 2000 to December 2002 were used 
to analyze utilization of the SSRI class (consisting of the
following: Celexa, Zoloft, Paxil, Effexor XR, Prozac, 
and ﬂuoxetine). Utilization data for each drug in the class
were separated into two group periods, pre- and post
introduction of generic ﬂuoxetine. The pre- and post
periods consisted of 19 and 17 months respectively. Uti-
lization of Prozac and ﬂuoxetine was used as a reference
to compare utilization of other drugs in the class. T-test
analysis was used to compare and show differences
between pre- and post-periods for each drug. RESULTS:
Prozac/ﬂuoxetine average monthly prescription utiliza-
tion for pre- and post-periods were 3434.16 and 4349.56
respectively (p < 0.001), which indicates an average
increase in monthly utilization by 27%. Celexa average
monthly utilization for pre- and post-periods were
1252.95 and 2848.4 respectively (p < 0.001), demon-
strating an increase in utilization by 127%. Effexor XR
average monthly utilization during pre- and post-periods
were 908.58 and 2084.38 respectively (p < 0.001), indi-
cating an increase of 129%. Paxil average monthly uti-
lization for pre- and post periods were 2834.9 and 4059.6
respectively (p < 0.001), indicating an increase of 43%.
Lastly, Zoloft’s average monthly utilization for pre- and
post periods were 3915.05 and 4615.88 respectively 
(p < 0.001), which resulted in an increase of 18%. 
CONCLUSION: In this managed care setting a signiﬁ-
cant increase in monthly utilization was seen for all drugs
with the exception of Zoloft.
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OBJECTIVES: Adopting new medical therapies is a
complex decision that must take into account many
factors, including differences in efﬁcacy, tolerability,
safety, and costs. Long-term comparative trials, especially
among newer antiepileptic drugs (AEDs), are lacking,
therefore decision models are needed to guide treatment
decisions. We aimed to develop an economic model of the
treatment of refractory epilepsy in the UK, and to assess
the cost-effectiveness of topiramate as adjunctive treat-
ment in refractory epilepsy compared to other newer
AEDs. METHODS: A Markov model was developed to
combine data from published clinical trials, cost-of illness
studies, epilepsy-related mortality surveys, and utility
studies. The expected costs and utilities associated with
possible treatment strategies (1st and 2nd line add-on
treatments) for newly diagnosed epilepsy patients with
partial seizures were calculated and compared. In those
patients requiring a second-line add-on, it was assumed
that the ﬁrst-line add-on treatment was stopped. A 
probabilistic analysis was undertaken and the cost-
effectiveness frontier mapped. RESULTS: First and
second-line adjunctive treatment with topiramate fol-
lowed by levetiracetam was the least costly add-on strat-
egy, and this strategy had the highest probability of being
cost-effective at currently accepted values of the ceiling
ratio (<£30,000/QALY). Levetiracetam ﬁrst-line, fol-
lowed by topiramate second-line generated additional
QALYs, but was more expensive, and was optimal only
if the ceiling ratio fell between £30,000 to £60,000/
QALY. Scenarios combining sequences of topiramate and
lamotrigine deliver a few additional QALYs at substan-
tial additional costs (became optimal only if the ceiling
ratio was >£60,000/QALY), while adjunctive treatment
with levetiracetam and lamotirigine are both more expen-
sive and generate less QALYs than the other scenarios,
therefore cannot be preferred. CONCLUSIONS: This
model suggests that topiramate ﬁrst-line adjunctive treat-
ment followed by levetiracetam second-line (or vice versa)
are cost-effective treatment strategies in patients with
partial seizures refractory to other treatments.
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OBJECTIVES: As sales of anti-migraine prescription
medications increased by more than 10-fold between
1994 and 1999, it is important to quantify the impact on
the cost of migraine treatment. The objectives of this
study were to determine the direct costs of migraine in
the U.S. population and to stratify those costs by type of
medical care. METHODS: Retrospective analysis was
conducted of the 1999 Medical Expenditure Panel Survey.
The survey provided data from a nationally representa-
tive sample of 24,618 respondents and their medical care
and health insurance providers. Data utilized in this study
included medical conditions and use and payments for
medical care. Migraineurs were identiﬁed using ICD-9-
CM codes and direct costs were calculated using patient
and third-party payments for migraine related medical
events by type of medical care. Sample estimates were
projected to the population and 95% conﬁdence limits
were calculated using the Taylor expansion method.
RESULTS: Direct costs incurred per migraineur were
$293. Total direct costs of migraine were
$1,429,053,413. The highest proportion of these costs
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was for prescription medications, at $747,551,471 (mean
= $59.87; 95% CL = $51.95–$67.78). Ofﬁce-based
medical provider visits were $396,946,065 (mean =
$73.50; 95% CL = $60.20–$86.80). Emergency depart-
ment visits were approximately $110 million while out-
patient services, inpatient stays, and home health services
were each below $100 million. CONCLUSIONS: The
cost of treating a migraineur was estimated to be $293 in
1999, nearly 3 times higher than $100 reported in 1994.
However, total direct costs in 1999 were $1.5 billion,
only 50% higher than $1 billion reported in 1994. 
Prescription expenditures at greater than 50% of direct
costs were a major factor in the increase in incident cost.
The rate of increase in total costs was less than the rate
of increase in incident costs, suggesting either greater drug
efﬁcacy or reduced use of more costly medical care 
alternatives.
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OBJECTIVES: There is a wide array of pharmacological
agents available for the acute treatment of migraine
headache. The 5-HT1B/1D receptor agonists (triptans),
ergotamine derivatives, and isometheptene/dichlo-
ralphenazone combination products represent the most
frequently prescribed migraine-speciﬁc therapies. Our
objective is to describe the costs and explore the 
utilization patterns of migraine-speciﬁc therapies in the
Wisconsin Medicaid population. METHODS: Wisconsin
Medicaid drug utilization data for 2001 was used. These
data were obtained directly from the Centers for
Medicare & Medicaid Services website. National Drug
Codes were used to extract quarterly utilization data for
products belonging to three classes of acute migraine ther-
apies (triptans, ergotamine derivatives, and isomethep-
tene/dichloralphenazone combination products). Analysis
of utilization was performed for each quarter of 2001 by
aggregating the amount and number of claims reimbursed
across products. Further analysis was conducted to
examine the average cost per claim between pharma-
cological classes and individual triptan therapies.
RESULTS: In 2001, the Wisconsin Medicaid program
reimbursed acute-migraine drug treatment claims totaling
$2,372,463.66, representing 15,120 prescription claims.
Most of this expenditure (98.3%/$2,331,090.71) was 
a result of triptan claims, with 1.5 % ($34,715.25) and
0.2% ($6,657.70) representing ergotamine derivative and
isometheptene/dichloralphenazone combination product
claims, respectively. Within the triptan class, sumitriptan
(9,122/$1,599,212.19), rizatriptan (2,388/$306,947.59)
and zolmatriptan (1,877/$264,947.76) composed the
ﬁrst, second, and third most utilized products. Cost per
claim values within the oral triptans varied greatly 
with a high of $180.72 (sumitriptan) and a low of $81.51
(almotriptan). CONCLUSION: In the Wisconsin Medic-
aid population, utilization of migraine-speciﬁc therapies
was weighted heavily towards the triptans. With the large
variation in claims cost among oral triptans, consider-
able cost savings could be realized if a system was 
implemented to increase utilization of newer, second-
generation triptans (non-sumatriptan) as ﬁrst-line
therapy. However, such a clinical decision should be sup-
ported by comparative clinical trail data that supports
equivalent or superior efﬁcacy to sumatriptan.
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OBJECTIVE: Clinical recommendations advocate use of
carbamazepine, lamotrigine, and gabapentin rather than
phenobarbital and phenytoin for treating older patients
with epilepsy. We describe prescribing patterns for 
older veterans newly diagnosed with epilepsy, determine
if practice is consistent with clinical recommendations,
and describe those at greatest risk of receiving these
potentially inappropriate antiepileptic drugs (AEDs).
METHODS: Retrospective national inpatient, outpatient,
and pharmacy data from the Veterans Health Adminis-
tration (VA), were used to identify veterans >64 years
with an epilepsy diagnosis during ﬁscal year 1999 (FY99)
who also received AEDs from the VA in FY99. Patients
who were seen in the VA during FY97-98 with no 
previous diagnosis of epilepsy were selected. We identi-
ﬁed patients’ AED regimen for FY99, demographic char-
acteristics, neurology consultations, and disease severity.
We used logistic regression to identify patients most likely
to receive phenobarbital and phenytoin. RESULTS:
Eighty-ﬁve percent received monotherapy. Ten percent 
of patients received regimens containing phenobarbital,
68% received regimens including phenytoin, and 25%
received only recommended AEDs. Logistic regression
analyses indicated that patients with more severe disease
were less likely to receive phenobarbital monotherapy
than other monotherapy (OR: 0.47, 95% CI 0.22–0.98)
and phenobarbital combinations than other combina-
tions (OR: 0.29, 95% CI 0.13–0.70). Patients receiving
neurology consultation were less likely to receive pheny-
toin monotherapy than monotherapies consistent with
clinical recommendations (New OR: 0.49, 95% CI
0.39–0.61). CONCLUSIONS: A surprising number of
newly diagnosed veterans received phenobarbital despite
its well known adverse effects. Moreover, our ﬁnding 
that nearly 70% receive phenytoin is not consistent with
